ES2542694T3 - Composición que comprende ácidos grasos omega 3 y un sal de cobre enmascarada o recubierta - Google Patents

Composición que comprende ácidos grasos omega 3 y un sal de cobre enmascarada o recubierta Download PDF

Info

Publication number
ES2542694T3
ES2542694T3 ES08718009.7T ES08718009T ES2542694T3 ES 2542694 T3 ES2542694 T3 ES 2542694T3 ES 08718009 T ES08718009 T ES 08718009T ES 2542694 T3 ES2542694 T3 ES 2542694T3
Authority
ES
Spain
Prior art keywords
omega
fatty acids
masked
copper
copper salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08718009.7T
Other languages
English (en)
Inventor
Georg Ludwig Kis
Jacques Vandermander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39477329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2542694(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP07104792A external-priority patent/EP1974733A1/en
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2542694T3 publication Critical patent/ES2542694T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
    • A23P20/10—Coating with edible coatings, e.g. with oils or fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Una composición farmacéutica que comprende uno o más ácidos grasos omega 3 sensibles al cobre y una sal de cobre enmascarada o recubierta para estabilizar la composición farmacéutica frente a la descomposición dependiente de la sal de cobre.

Description

imagen1
E08718009
15-07-2015
Gelatina 175 bloom bovina Glicerol al 99 %,USP Aceite de soja en copos (hidrogenado), NF Aceite de soja USP y
Colorantes (si es necesario) orgánicos y/o inorgánicos, por ejemplo, dióxido de titanio USP, óxido de hierro negro E172 y/o óxido de hierro rojo E172
La estabilidad de la composición anterior se investiga en un entorno donde el cobre no está enmascarado y en una
5 situación en la que el cobre está enmascarado en la cubierta y que, por consiguiente, no está en contacto directo con los ingredientes sensibles al cobre. La estabilidad del procedimiento de enmascaramiento/recubrimiento descrito se correlaciona con el grado de descomposición de tal compuesto y/o composición sensibles al cobre.
Ejemplo 3
240 mg de aceite de pescado con DHA al 70 % etiquetado 160 mg de ácidos grasos omega 3Ácido docosahexaenoico (DHA) etiquetado 130 mg de DHAÁcido eicosapentaenoico (EPA) como parte del aceite de pescado etiquetado 11 mg 91,5 mg de ascorbato de calcio etiquetado 60 mg de vitamina C 31,343 mg de acetato de d,l-alfa-tocoferol etiquetado 20 mg de vitamina E 55 mg de luteína al 20 % en aceite de alazor etiquetado 10 mg de luteína 12,447 mg de óxido de cinc etiquetado 10 mg de cinc 0,45 mg de carbonato cúprico básico etiquetado 0,25 mg de cobre Zeaxantina como parte de la luteína etiquetado 0,8 mg
La composición anterior puede contener otros excipientes para la producción de una formulación galénica deseada, 10 por ejemplo, para fabricar una cubierta de una cápsula o similar.
Ejemplo 4
Estabilidad de ácidos grasos omega 3 en cápsulas blandas de gelatina después de 2 días de almacenamiento a 80 [grados] C. (Humedad ambiental, es decir, humedad relativa del 50-70 %)
(Cambio en el contenido de los componentes de ácido graso omega 3)
15 Los ensayos para cuantificar el porcentaje en peso de EPA y DHA después del almacenamiento se llevan a cabo por cromatografía de gases por el procedimiento habitual descrito en la Farmacopea Europea 5.4.
Componentes de ácidos grasos omega 3
Formulación con cobre no enmascarado Formulaciones con cobre enmascarado
Formulaciones desveladas en el ejemplo 3: (con carbonato cúprico básico). La cubierta es idéntica a la cubierta desvelada en el ejemplo 2, pero no contiene cobre
Formulación como se desvela en el ejemplo 3, en la que se reemplaza el carbonato cúprico básico con 2,250 mg de DESCOTE® (gluconato de cobre recubierto), que corresponden a 0,25 mg de cobre. La cubierta es idéntica a la cubierta desvelada en el ejemplo 2, pero no contiene cobre Formulación desvelada en el ejemplo 3, si bien se omite el cobre de dicha formulación. No obstante hay cobre en la cubierta, a saber, 0,45 mg de carbonato cúprico básico (que corresponden a 0,25 mg de cobre), como se desvela en el ejemplo 2
EPA en % en peso
disminución del 5,0 % disminución del 1,7 % sin cambios (sin disminución)
DHA en % en peso
Sin cambios detectables Sin cambios detectables sin cambios (sin disminución)
Otros ácidos grasos omega 3** distintos de EPA y DHA en % en peso
disminución del 1,9 % disminución del 0,4 % sin cambios (sin disminución)
**Otros ácidos grasos omega 3 denota la suma de ácido alfa-linolénico (ALA), ácido estearidónico (SA), ácido eicosatetraenoico (ETA) y ácido docosapentaenoico (DPA).
3
imagen2

Claims (1)

  1. imagen1
ES08718009.7T 2007-03-23 2008-03-19 Composición que comprende ácidos grasos omega 3 y un sal de cobre enmascarada o recubierta Active ES2542694T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07104792A EP1974733A1 (en) 2007-03-23 2007-03-23 Use of a masked or coated copper salt for the treatment of macular degeneration
EP07104792 2007-03-23
EP07111322 2007-06-28
EP07111322 2007-06-28
PCT/EP2008/053283 WO2008116806A1 (en) 2007-03-23 2008-03-19 Use of a masked or coated copper salt for the treatment of macular degeneration

Publications (1)

Publication Number Publication Date
ES2542694T3 true ES2542694T3 (es) 2015-08-10

Family

ID=39477329

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08718009.7T Active ES2542694T3 (es) 2007-03-23 2008-03-19 Composición que comprende ácidos grasos omega 3 y un sal de cobre enmascarada o recubierta

Country Status (26)

Country Link
US (1) US20080233182A1 (es)
EP (1) EP2124973B1 (es)
JP (1) JP2010521534A (es)
KR (1) KR101688656B1 (es)
AR (1) AR065791A1 (es)
AU (1) AU2008231847B2 (es)
BR (1) BRPI0809258B8 (es)
CA (1) CA2681514C (es)
CL (1) CL2008000804A1 (es)
CO (1) CO6230993A2 (es)
DK (1) DK2124973T3 (es)
EC (1) ECSP099700A (es)
ES (1) ES2542694T3 (es)
GT (1) GT200900251A (es)
IL (1) IL201109A (es)
MA (1) MA31293B1 (es)
MX (1) MX2009010244A (es)
MY (1) MY164520A (es)
NZ (1) NZ579852A (es)
PE (1) PE20090186A1 (es)
PL (1) PL2124973T3 (es)
PT (1) PT2124973E (es)
RU (1) RU2009139002A (es)
TN (1) TN2009000387A1 (es)
TW (1) TW200904456A (es)
WO (1) WO2008116806A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9532963B2 (en) * 2009-03-09 2017-01-03 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof
KR101759255B1 (ko) 2015-09-18 2017-07-18 한국산업기술대학교산학협력단 무촉매 방식 가변경사각을 갖는 나노 구조물 성장 방법
AR118962A1 (es) * 2019-05-22 2021-11-10 Bayer Consumer Care Ag Preparaciones de cápsulas de gelatina blanda de vitaminas y minerales que comprenden vitamina c en forma de una sal de ascorbato

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2043487A1 (es) * 1969-05-28 1971-02-19 Commissariat Energie Atomique
US5298237A (en) * 1992-01-24 1994-03-29 The Trustees Of Columbia University In The City Of New York Gel composition for reduction of gingival inflammation and retardation of dental plaque
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US20030004043A1 (en) * 2001-06-27 2003-01-02 Deola James A. Pivoting backrest for exercise apparatus
US20030104043A1 (en) * 2001-12-03 2003-06-05 Brown Beverly Ann Topical cream for alleviating spider veins
US20050249820A1 (en) * 2004-05-04 2005-11-10 Akorn, Inc. Nutritional supplement for the treatment and prevention of macular degeneration
US7887847B2 (en) * 2004-05-08 2011-02-15 Paul Jr Edward L Nutritional supplement for treatment of ocular diseases
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
NZ552451A (en) * 2004-07-09 2010-07-30 Robert Sabin Compositions and methods of use for treatment of mammalian diseases
JP2008520739A (ja) * 2004-11-19 2008-06-19 マーテック・バイオサイエンシーズ・コーポレーション 長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製および使用方法

Also Published As

Publication number Publication date
AU2008231847B2 (en) 2012-12-06
KR101688656B1 (ko) 2016-12-21
BRPI0809258B8 (pt) 2021-05-25
MY164520A (en) 2017-12-29
WO2008116806A1 (en) 2008-10-02
ECSP099700A (es) 2009-11-30
IL201109A0 (en) 2010-05-17
BRPI0809258B1 (pt) 2019-10-01
DK2124973T3 (da) 2015-06-22
PE20090186A1 (es) 2009-03-20
TW200904456A (en) 2009-02-01
BRPI0809258A2 (pt) 2014-09-23
CO6230993A2 (es) 2010-12-20
JP2010521534A (ja) 2010-06-24
CA2681514A1 (en) 2008-10-02
MX2009010244A (es) 2009-10-26
TN2009000387A1 (en) 2010-12-31
EP2124973B1 (en) 2015-05-27
RU2009139002A (ru) 2011-04-27
EP2124973A1 (en) 2009-12-02
AU2008231847A1 (en) 2008-10-02
CA2681514C (en) 2016-11-08
GT200900251A (es) 2018-10-08
NZ579852A (en) 2012-03-30
PL2124973T3 (pl) 2015-10-30
CL2008000804A1 (es) 2008-10-24
AR065791A1 (es) 2009-07-01
KR20100015799A (ko) 2010-02-12
MA31293B1 (fr) 2010-04-01
PT2124973E (pt) 2015-09-01
US20080233182A1 (en) 2008-09-25
IL201109A (en) 2016-10-31

Similar Documents

Publication Publication Date Title
de Barboza et al. Oxidative stress, antioxidants and intestinal calcium absorption
Trebatická et al. Cardiovascular diseases, depression disorders and potential effects of omega-3 fatty acids
Generoso et al. Dietary supplementation with omega-3 fatty acid attenuates 5-fluorouracil induced mucositis in mice
RU2009126735A (ru) Композиция питательной добавки, предназначенной для лечения глазных болезней
MXPA06008352A (es) Una composicion farmaceutica.
EA200100895A1 (ru) Незаменимые жирные кислоты для предотвращения сердечно-сосудистых приступов
Moura Rocha et al. Gastroprotection of (‐)‐α‐bisabolol on acute gastric mucosal lesions in mice: the possible involved pharmacological mechanisms
EP1470817A4 (en) COMPOSITIONS FOR PREVENTING CANCER IN HUMANS AND METHOD FOR PREVENTING CANCER IN HUMANS
Silva et al. Alendronate induces gastric damage by reducing nitric oxide synthase expression and NO/cGMP/KATP signaling pathway
ITMI20072051A1 (it) Composizione a base di pellet di acido lipoico
Trattner et al. Effects of α-lipoic and ascorbic acid on the muscle and brain fatty acids and antioxidant profile of the South American pacu Piaractus mesopotamicus
Puskás et al. Polyunsaturated fatty acids synergize with lipid droplet binding thalidomide analogs to induce oxidative stress in cancer cells
Kangwan et al. Development of GI-safe NSAID; progression from the bark of willow tree to modern pharmacology
Komsky-Elbaz et al. Atrazine-induced toxicity in goat spermatozoa is alleviated to some extent by polyphenol-enriched feed
Nasadyuk et al. Thymohexin exhibits cytoprotective effect in experimental gastric lesions in rats both through the inhibition of inducible nitric oxide synthase and reduction of oxidative mucosal damage
Barcelos et al. Effects of ω-3 essential fatty acids (ω-3 EFAs) on motor disorders and memory dysfunction typical neuroleptic-induced: behavioral and biochemical parameter
Tenore et al. Canned bluefin tuna, an in vitro cardioprotective functional food potentially safer than commercial fish oil based pharmaceutical formulations
ES2531599T3 (es) Utilización de triglicéridos docosahexaenoicos para el tratamiento de enfermedades tumorales
RU2007117803A (ru) Композиция для лечения глаз, содержащая омега-3 жирные кислоты и омега-6 жирные кислоты
EP1714658B1 (fr) Complément alimentaire comprenant une association d'agents antioxydants et de la carnitine ou un précurseur de la carnitine, comme aide à la fertilité chez l'homme et chez la femme
Alizadeh et al. Dietary vitamin E is more effective than omega-3 and omega-6 fatty acid for improving the kinematic characteristics of rat sperm
KR101688656B1 (ko) 차폐 또는 코팅된 구리염의 황반 변성의 치료를 위한 용도
Othman Evaluation of gastric tolerability for long-term use of diclofenac and celecoxib in male albino rats and potential gastroprotective benefits of royal jelly: a randomized controlled trial
AR070405A1 (es) Composiciones para la prevencion y/o el tratamiento de la degeneracion macular y/o la perdida de la agudeza visual
FR2760358A1 (fr) Composition cosmetique et pharmaceutique revigorante, notamment permettant d'eviter aux cheveux de devenir blancs avec l'âge, et aussi de reprendre leur couleur d'origine s'ils sont deja blancs